216 related articles for article (PubMed ID: 27813409)
1. β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.
Hager MV; Johnson LM; Wootten D; Sexton PM; Gellman SH
J Am Chem Soc; 2016 Nov; 138(45):14970-14979. PubMed ID: 27813409
[TBL] [Abstract][Full Text] [Related]
2. Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.
Cary BP; Hager MV; Gellman SH
Chembiochem; 2019 Nov; 20(22):2834-2840. PubMed ID: 31172641
[TBL] [Abstract][Full Text] [Related]
3. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D
Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
[TBL] [Abstract][Full Text] [Related]
5. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
6. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
[TBL] [Abstract][Full Text] [Related]
7. The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment and internalisation.
McNeill SM; Lu J; Marion C Carino C; Inoue A; Zhao P; Sexton PM; Wootten D
Biochem Pharmacol; 2024 Apr; 222():116119. PubMed ID: 38461904
[TBL] [Abstract][Full Text] [Related]
8. Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice.
Gabe MBN; von Voss L; Hunt JE; Gadgaard S; Gasbjerg LS; Holst JJ; Kissow H; Hartmann B; Rosenkilde MM
Br J Pharmacol; 2023 Jul; 180(13):1674-1689. PubMed ID: 36683195
[TBL] [Abstract][Full Text] [Related]
9. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells.
Sonoda N; Imamura T; Yoshizaki T; Babendure JL; Lu JC; Olefsky JM
Proc Natl Acad Sci U S A; 2008 May; 105(18):6614-9. PubMed ID: 18445652
[TBL] [Abstract][Full Text] [Related]
10. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
11. The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation.
Estall JL; Koehler JA; Yusta B; Drucker DJ
J Biol Chem; 2005 Jun; 280(23):22124-34. PubMed ID: 15817468
[TBL] [Abstract][Full Text] [Related]
12. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
13. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s).
Jorgensen R; Kubale V; Vrecl M; Schwartz TW; Elling CE
J Pharmacol Exp Ther; 2007 Jul; 322(1):148-54. PubMed ID: 17395766
[TBL] [Abstract][Full Text] [Related]
14. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
Nakane A; Gotoh Y; Ichihara J; Nagata H
Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
17. Effects of Replacing a Central Glycine Residue in GLP-1 on Receptor Affinity and Signaling Profile.
Brown KA; Gellman SH
Chembiochem; 2023 Nov; 24(21):e202300504. PubMed ID: 37624685
[TBL] [Abstract][Full Text] [Related]
18. A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo.
Johnson LM; Barrick S; Hager MV; McFedries A; Homan EA; Rabaglia ME; Keller MP; Attie AD; Saghatelian A; Bisello A; Gellman SH
J Am Chem Soc; 2014 Sep; 136(37):12848-51. PubMed ID: 25191938
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
Thompson A; Stephens JW; Bain SC; Kanamarlapudi V
PLoS One; 2016; 11(4):e0154229. PubMed ID: 27100083
[TBL] [Abstract][Full Text] [Related]
20. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
